Healthy Foods & Nutrition Lab de Mexico shipped hand sanitizer labeled 70% alcohol that tested at 13%, and lacked drug approval.
What happened
FDA laboratory-tested a batch of the firm's HF & NLab Verio Healthcare Alcohol Antiseptic Topical Solution that had been stopped at the U.S. border, and found it contained an average of only 13% ethanol instead of the 70% stated on the label. In a July 29, 2020 call, FDA recommended the firm remove its hand sanitizers from the U.S. market; the firm first called the subpotent batch an isolated incident, then wrote on August 7, 2020 that it had other subpotent batches, and as of the letter had taken no market action. FDA placed all of the firm's drugs on Import Alert 66-78 on August 13, 2020, meaning its products can be detained at the border without physical examination.
What FDA found
The hand sanitizer was labeled as 70% ethanol but tested at about 13%, so its strength was below what it claimed.
Section 501(c) of the FD&C Act, 21 U.S.C. 351(c)Multiple subpotent batches show the firm's quality assurance was not working as required by Current Good Manufacturing Practice (CGMP, the basic quality rules for making drugs).
Section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)The product is a new drug sold without FDA approval and does not qualify for marketing without one.
Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)The label statement of 70% ethanol is false and misleading, which makes the product misbranded.
Section 502(a) of the FD&C Act, 21 U.S.C. 352(a)The label does not give a U.S. address or phone number where the responsible person can receive reports of serious adverse events.
Section 502(x) of the FD&C Act, 21 U.S.C. 352(x)The product does not meet the conditions for nonprescription drugs marketed without an approved application.
Section 502(ee) of the FD&C Act, 21 U.S.C. 355h
What FDA wants
FDA wants a written response within 15 working days that includes a detailed investigation of how the 70% product came to contain 13% ethanol, a list of raw materials and suppliers, batch records and distribution reconciliation for all U.S. shipments, and independent assessments of the firm's quality unit and laboratory practices, plus process validation protocols. FDA also strongly recommends hiring a qualified CGMP consultant and requests a Regulatory Meeting if the firm wants to make drugs for the U.S. in the future.
Who should pay attention
- distributors and retailers that sold this hand sanitizer
- brands that contract-manufacture drug products in Mexico
- companies that rely on a supplier's certificate of analysis for active ingredient strength
This is a summary. Read the original letter on fda.gov.